Related Experiment Video
Updated: Mar 1, 2026
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
[Allergic bronchopulmonary aspergillosis: Evaluation of a maintenance therapy with nebulized Ambisome®]
C Godet1, F Couturaud2, S Ragot3
1Service de maladies infectieuses et de médecine interne, CHU de Poitiers, 2, rue de la Miletrie, 86021 Poitiers cedex, France.
Background:
Allergic bronchopulmonary aspergillosis (ABPA) affects 3-13% of patients with asthma. Its natural history includes possibly life-threatening exacerbations and evolution towards fixed obstructive ventilatory disorders or even irreversible lung fibrosis lesions. ABPA prognosis is directly associated with exacerbation control and the main objective of the treatment is to decrease their frequency and duration. Recommendations regarding dosage and duration of treatment are not very precise. The currently used combination of itraconazole and corticosteroid therapy has many limitations. The interests of a therapeutic strategy using nebulized liposomal amphotericin B (LAmB) are to heighten antifungal lung tissue concentration, to circumvent drug interactions and decrease the potential toxicity of systemic antifungal treatments. Finally, this association leads to improved eradication of Aspergillus, thereby limiting the risk of side effects and the emergence of treatment-resistant Aspergillus strains.
Methods:
This is a phase II, multicentre, randomized, single blind, controlled therapeutic study, with the objective of comparing the potential benefit on exacerbation control of a maintenance therapy by LAmB nebulization. The main objective of the study is to compare the incidence of severe clinical exacerbations in ABPA treatment, between a maintenance treatment strategy with nebulized LAmB and a conventional strategy without antifungal maintenance therapy.
Expected Results:
The results will guide practitioners in the management of ABPA treatments and help to define the place of aerosols of LAmB on "evidence base medicine" criteria.
Insights
Nebulized liposomal amphotericin B (LAmB) may improve allergic bronchopulmonary aspergillosis (ABPA) exacerbation control. This study compares LAmB maintenance therapy against conventional treatment to assess its effectiveness in reducing severe exacerbations.
Area of Science:
- Pulmonology
- Infectious Diseases
- Clinical Therapeutics
Background:
- Allergic bronchopulmonary aspergillosis (ABPA) affects 3-13% of asthma patients, potentially leading to severe lung damage.
- Current treatments for ABPA have limitations, and prognosis depends on controlling exacerbations.
Purpose of the Study:
- To evaluate the efficacy of nebulized liposomal amphotericin B (LAmB) as a maintenance therapy for ABPA.
- To compare the incidence of severe clinical exacerbations in ABPA patients receiving LAmB maintenance versus conventional therapy.
Main Methods:
- Phase II, multicenter, randomized, single-blind, controlled therapeutic study.
- Comparison of a maintenance therapy strategy using nebulized LAmB against a conventional strategy without antifungal maintenance.
- Primary endpoint: incidence of severe clinical exacerbations in ABPA.
Main Results:
- Expected results will guide ABPA treatment management.
- The study aims to establish the role of nebulized LAmB in evidence-based medicine for ABPA.
Conclusions:
- Nebulized LAmB offers a potential strategy to enhance antifungal lung concentration and reduce systemic drug toxicity.
- This approach may improve Aspergillus eradication, minimizing side effects and resistance development.
More Related Videos
09:52Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis
Published on: March 9, 2018
12:27The Utilization of Oropharyngeal Intratracheal PAMP Administration and Bronchoalveolar Lavage to Evaluate the Host Immune Response in Mice
Published on: April 2, 2014
Related Concept Videos
01:30Asthma-IV: Nursing Management
First, in...
01:23Inhaled Medications
01:30Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:29Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...